Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection.
Viruses
; 14(2)2022 01 19.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1625815
ABSTRACT
SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19 pandemic. Currently, there is still an urgent need in developing an efficient therapeutic intervention. In this study, we aimed at evaluating the therapeutic effect of a single intranasal treatment of the TLR3/MDA5 synthetic agonist Poly(IC) against a lethal dose of SARS-CoV-2 in K18-hACE2 transgenic mice. We demonstrate here that early Poly(IC) treatment acts synergistically with SARS-CoV-2 to induce an intense, immediate and transient upregulation of innate immunity-related genes in lungs. This effect is accompanied by viral load reduction, lung and brain cytokine storms prevention and increased levels of macrophages and NK cells, resulting in 83% mice survival, concomitantly with long-term immunization. Thus, priming the lung innate immunity by Poly(IC) or alike may provide an immediate, efficient and safe protective measure against SARS-CoV-2 infection.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Poli I-C
/
Receptor Toll-Like 3
/
SARS-CoV-2
/
COVID-19
/
Inmunidad Innata
Tipo de estudio:
Estudio experimental
/
Estudio pronóstico
Límite:
Animales
/
Femenino
/
Humanos
Idioma:
Inglés
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
V14020189
Similares
MEDLINE
...
LILACS
LIS